BioPharmSignal logoBioPharmSignal

Biotech News

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Immuneering (IMRX)ImmuneeringConference / presentation

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences

Related news

IMRXImmuneering2026-08-05 11:30 EST

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

IMRXImmuneering2026-06-11 11:30 EST

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

GSKGSK plc2026-07-21 10:28 EST

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026

View all latest news

Immuneering

Deep Cyclic Inhibitors Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity. Atebimetinib Atebimetinib is an oral, once-daily...

Recent company news

IMRXImmuneering2026-08-05 11:30 EST

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

IMRXImmuneering2026-07-21 20:05 EST

Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

IMRXImmuneering2026-07-17 20:05 EST

Immuneering Corporation Announces Grants of Inducement Awards

IMRXImmuneering2026-06-15 11:30 EST

Immuneering Appoints Andrew Gengos as Chief Financial Officer

IMRXImmuneering2026-06-11 11:30 EST

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Stock data

Close
5.30 USD
Market cap
276.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States